Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized single-blind study of cefepime + nacubactam or aztreonam + nacubactam versus best available therapy for carbapenem-resistant Enterobacterales infections
MOH_2023-03-01_012384Phase 3Recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Feb 2023
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Nacubactam, cefepime and aztreonam in Enterobacterales infection, complicated urinary tract infection (cUTI), acute pyelonephritis and 3 more (3 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoints: Overall treatment success by composite assessment across infection types and Safety of intravenous cefepime + nacubactam and aztreonam + nacubactam. Started Feb 2023; status: recruiting.
02
Drugs
Nacubactamcefepimeaztreonam
03
Conditions
Enterobacterales infectioncomplicated urinary tract infection (cUTI)acute pyelonephritishospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on MOH_2023-03-01_012384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-01_012384.